Catherine Alix-Panabières, Director of the Laboratory of Rare Human Circulating Cells and Professor of Universities – Hospital Practitioner at Montpellier University Hospital, shared a post on LinkedIn:
“Delighted to share our new article review published by HORIBA after my conference presentation at Horiba Kyoto in Japan:
‘Liquid Biopsy in Cancer Management: Advances, Challenges, and Emerging Clinical Applications‘ Doryan Masmoudi and Catherine Alix-Panabières
Liquid Biopsy is transforming how we understand and manage cancer.
By analyzing tumor-derived components in blood, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs) – this approach offers a minimally invasive and dynamic window into tumor heterogeneity and disease evolution.
Recent technological advances have significantly expanded its potential, from early detection and minimal residual disease (MRD) monitoring to treatment response evaluation and therapy guidance.
Yet, key challenges remain. Biological complexity, technical variability, and the lack of standardized workflows continue to limit widespread clinical adoption.
In this review, we explore:
- Current methodologies and clinical applications
- The complementary value of different circulating analytes
- Emerging innovations, including multi-omics integration and AI-driven analysis
- Future priorities: standardization, multicenter trials, and integration into routine oncology practice
The path forward is clear: collaboration, harmonization, and innovation will be essential to unlock the full clinical potential of liquid biopsy.”
Title: Liquid Biopsy in Cancer Management: Advances, Challenges, and Emerging Clinical Applications
Authors: Doryan Masmoudi and Catherine Alix-Panabières
Other articles featuring Catherine Alix-Panabières and Doryan Masmoudi on OncoDaily.